At GeneproDX, we combine genomics and artificial intelligence to transform cancer diagnosis into a simple and fast process. Our goal is to provide diagnostic certainty, optimizing cancer treatment, reducing costs and avoiding unnecessary therapies. Thanks to our innovative tests, patients and doctors can make decisions based on precise and timely diagnoses.
Our mission at GeneproDX is to provide physicians and patients worldwide with the highest standard of precision medicine for indeterminate thyroid nodules through our innovative solution, ThyroidPrint®.
At GeneproDX, our vision is to pioneer and lead global diagnostic solutions for patients with indeterminate thyroid nodules, continually driving innovation and maintaining the highest quality standards. We strive to help physicians worldwide resolve uncertainty in patient care by harnessing the power of Artificial Intelligence in molecular testing.
A research group led by Dr. Hernán González is formed at the Oncology Laboratory of the School of Medicine at the Pontifical Catholic University of Chile.
In 2007, he participated in an entrepreneurship program in Silicon Valley, presenting his thyroid cancer detection test. Despite initial setbacks, he pursued funding from Corfo and BMRC for the development and validation of the ThyroidPrint® test in biotechnology.
2017 - Publication of the prototype development of the test, with a cohort of 1,300 patients in Chile:
"Thyroid 2017 Aug. 27(8): 1058-1067. Doi: 10.2089thy 2017.0067"
In 2019, the technology used by ThyroidPrint® was patented. This patent has been granted in Europe, the United States, Canada, Brazil, China, South Korea, Japan, Australia, and South Africa.
Due to the pandemic, GeneproDX partnered with the Pontifical Catholic University of Chile's "Proyecto Esperanza" for SARS-CoV-2 detection. This made GeneproDX an authorized lab by the Ministry of Health and expanded its services to respiratory patients under the GENEPRO brand. They offered COVID-19 testing until December 31, 2022.
Starting from mid-2022, GeneproDX resumed the centralized service for the ThyroidPrint® test until the present date.
In GeneproDX, our passion for innovation and positive impact on health drives us to make a global difference. We look towards a promising future, making genetic medicine accessible to all and empowering individuals with valuable information to enhance their lives.
ThyroidPrint® was developed to predict benignity of indeterminate thyroid nodules using an innovative microfluidics real-time PCR technology and a neural network-based algorithm analysis. ThyroidPrint® is able to safely forgo unnecessary diagnostic thyroid surgery in 2/3rd of patients.
It provides the following performance parameters: Sensitivity 91%, Specificity 88%, Negative Predictive Value 95% and Positive Predictive Value of 78%
Thanks to the partnership between GeneproDX and Biocartis®, ThyroidPrint® becomes the world’s only decentralized molecular test for thyroid nodules through the Idylla™ platform, allowing hospitals to conduct the analysis directly on-site.
Scan sample & Cartridge
Insert Sample in the Cartridge
Insert cartridge in the Idylla™ System
and obtain the result within 3 hours
First-of-its-kind Molecular Test: Analyzed in the Hospital in Less Than 3 Hours
ThyroidPrint® can be analyzed directly in hospitals equipped with the Idylla™ platform.
Available globally thanks to Biocartis® presence in over 88 countries.
At GeneproDX, we are leading a global revolution in reclassify indeterminate thyroid nodules diagnostics. Our cutting-edge technology is expanding our presence beyond Europe and Latin America. Over the next two years, our determination and our descentralized model through Idylla™ Platform will take us to every corner of the world, providing patients and doctors with fast and accurate results.
Join us in creating a future where innovative tests unlock the answers to critical clinical questions, transforming treatment decisions and saving thyroids. Together, let's conquer the world avoiding thyroid unnecessary surgeries!